Ventyx Biosciences, Inc. (VTYX)
NASDAQ: VTYX · Real-Time Price · USD
13.97
0.00 (0.00%)
At close: Feb 27, 2026, 4:00 PM EST
13.99
+0.02 (0.14%)
After-hours: Feb 27, 2026, 7:07 PM EST
Ventyx Biosciences Market Cap
Ventyx Biosciences has a market cap or net worth of $1 billion as of February 27, 2026. Its market cap has increased by 775.15% in one year.
Market Cap
1.00B
Enterprise Value
819.88M
1-Year Change
775.15%
Ranking
Category
Stock Price
$13.97
Market Cap Chart
Since the IPO on October 21, 2021, Ventyx Biosciences's market cap has increased from $782.89M to $1.00B, an increase of 28.05%. That is a compound annual growth rate of 5.84%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 27, 2026 | 1.00B | 55.58% |
| Dec 31, 2025 | 644.37M | 316.11% |
| Dec 31, 2024 | 154.86M | 6.21% |
| Dec 29, 2023 | 145.80M | -92.15% |
| Dec 30, 2022 | 1.86B | 85.92% |
| Dec 31, 2021 | 998.89M | 27.59% |
| Oct 21, 2021 | 782.89M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Compass Therapeutics | 1.05B |
| Aktis Oncology | 1.02B |
| Valneva SE | 997.56M |
| CytomX Therapeutics | 979.34M |
| GH Research | 976.96M |
| SpyGlass Pharma | 970.54M |
| UroGen Pharma | 967.54M |
| Theravance Biopharma | 965.82M |